Journal of Clinical Endocrinology & Metabolism, Vol 71, 1168-1174, Copyright © 1990 by Endocrine Society

ARTICLES

Insulin-like growth factor-II: possible local growth factor in pheochromocytoma

MC Gelato and J Vassalotti
Division of Endocrinology, State University of New York, Stony Brook 11794.

Pheochromocytomas, neural crest tumors, express an abundance of insulin- like growth factor-II (IGF-II). To assess further the potential for IGF- II to play an autocrine role for these tumors, we measured 1) IGF-II content by RRA in 7 pheochromocytomas and peripheral blood in these patients, 2) IGF-II receptors by Western analysis, and 3) characterized the tumor binding proteins by ligand blot studies. IGF-II levels in the tumors varied from 2.8-41 micrograms/g. Chromatography revealed that 60% of the peptide eluted as a large mol wt form of IGF-II (8.7-10 kDa); the remainder coeluted with mature peptide (7.5 kDa). This was in contrast to IGF-II levels in normal adrenal tissue (0.225 +/- 0.005 micrograms/g) or another neural crest-derived tumor, medullary carcinoma of the thyroid (0.63 +/- 0.02 micrograms/g). Serum IGF-II levels in the 7 patients with pheochromocytoma (720 +/- 71 ng/mL) were similar to those in 35 normal controls (762 +/- 69 ng/mL). Radiolabeled IGF-II (9 +/- 1%) and IGF-I (20 +/- 2%) bound specifically to pheochromocytoma membranes. Western analysis of these membranes using a specific antiserum directed against the type II receptor demonstrated a band at 210 kDa. Affinity cross-linking studies with [125I]IGF-I demonstrated a specific band at 140 kDa. Ligand blot analysis was performed on the void volume pools from the Sephadex G-75 column and demonstrated bands at about 30 and 25 kDa. In conclusion, these data 1) confirm that pheochromocytomas have increased levels of IGF-II; 2) demonstrate that despite high IGF-II concentrations in the tumors, peripheral levels are not elevated, suggesting that very little tumoral IGF-II is released into the circulation, unlike catecholamines; 3) demonstrate the presence of IGF-II and IGF-I receptors; 4) describe binding protein species similar to those present in other tissues. Thus, the presence of high levels of IGF-II and both type I and type II receptors suggests that IGF II may act through both receptors to alter tumor growth.

This article has been cited by other articles:

				J. PUC, G. PLACHA, B. WOCIAL, K. PODSYPANINA, R. PARSONS, and Z. GACIONG Analysis of PTEN Mutation in Non-familial Pheochromocytoma. Ann. N.Y. Acad. Sci., August 1, 2006; 1073: 317 - 331. [Abstract] [Full Text] [PDF]

				C. Fottner, T. Minnemann, S. Kalmbach, and M. M Weber Overexpression of the insulin-like growth factor I receptor in human pheochromocytomas. J. Mol. Endocrinol., April 1, 2006; 36(2): 279 - 287. [Abstract] [Full Text] [PDF]

				H. Cui, M. Cruz-Correa, F. M. Giardiello, D. F. Hutcheon, D. R. Kafonek, S. Brandenburg, Y. Wu, X. He, N. R. Powe, and A. P. Feinberg Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk Science, March 14, 2003; 299(5613): 1753 - 1755. [Abstract] [Full Text] [PDF]

				J. D. Ravenel, K. W. Broman, E. J. Perlman, E. L. Niemitz, T. M. Jayawardena, D. W. Bell, D. A. Haber, H. Uejima, and A. P. Feinberg Loss of Imprinting of Insulin-Like Growth Factor-II (IGF2) Gene in Distinguishing Specific Biologic Subtypes of Wilms Tumor J Natl Cancer Inst, November 21, 2001; 93(22): 1698 - 1703. [Abstract] [Full Text] [PDF]

				A. Lacroix, N. N'Diaye, J. Tremblay, and P. Hamet Ectopic and Abnormal Hormone Receptors in Adrenal Cushing's Syndrome Endocr. Rev., February 1, 2001; 22(1): 75 - 110. [Abstract] [Full Text]